Systemic therapy options for unresectable and metastatic chordomas

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Chordoma is an exceedingly rare tumor, marked by a slow growth rate. Surgery is the treatment of choice, but the most frequent sites of origin (spine and skull base) make treatment of primary disease challenging. Local relapses affect more than 50% of cases, with a minority of patients being cured by further surgery. Furthermore, metastases occur in at least 20% of patients. For residual or recurrent disease, high-dose radiation therapy may be indicated. Radiation therapy is currently the preferred local treatment when surgery is problematic, exploiting most recent techniques, including proton beams and carbon ions. However, systemic therapy is needed in patients non-amenable to surgery and/or radiation therapy. We reviewed systemic treatments currently available, and targets possibly druggable in the future in this orphan disease.

Original languageEnglish
Pages (from-to)323-330
Number of pages8
JournalCurrent Oncology Reports
Volume13
Issue number4
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Chordoma
Radiotherapy
Therapeutics
Skull Base
Rare Diseases
Protons
Spine
Carbon
Ions
Neoplasm Metastasis
Recurrence
Growth
Neoplasms

Keywords

  • Bone sarcoma
  • Chemotherapy
  • Chordoma
  • Sarcomas
  • Systemic therapy options for unresectable and metastatic chordomas
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Systemic therapy options for unresectable and metastatic chordomas. / Stacchiotti, Silvia; Casali, Paolo Giovanni.

In: Current Oncology Reports, Vol. 13, No. 4, 08.2011, p. 323-330.

Research output: Contribution to journalArticle

@article{76709ceae70c4d41affcc47c6aa2a9b1,
title = "Systemic therapy options for unresectable and metastatic chordomas",
abstract = "Chordoma is an exceedingly rare tumor, marked by a slow growth rate. Surgery is the treatment of choice, but the most frequent sites of origin (spine and skull base) make treatment of primary disease challenging. Local relapses affect more than 50{\%} of cases, with a minority of patients being cured by further surgery. Furthermore, metastases occur in at least 20{\%} of patients. For residual or recurrent disease, high-dose radiation therapy may be indicated. Radiation therapy is currently the preferred local treatment when surgery is problematic, exploiting most recent techniques, including proton beams and carbon ions. However, systemic therapy is needed in patients non-amenable to surgery and/or radiation therapy. We reviewed systemic treatments currently available, and targets possibly druggable in the future in this orphan disease.",
keywords = "Bone sarcoma, Chemotherapy, Chordoma, Sarcomas, Systemic therapy options for unresectable and metastatic chordomas, Targeted therapy",
author = "Silvia Stacchiotti and Casali, {Paolo Giovanni}",
year = "2011",
month = "8",
doi = "10.1007/s11912-011-0176-x",
language = "English",
volume = "13",
pages = "323--330",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Systemic therapy options for unresectable and metastatic chordomas

AU - Stacchiotti, Silvia

AU - Casali, Paolo Giovanni

PY - 2011/8

Y1 - 2011/8

N2 - Chordoma is an exceedingly rare tumor, marked by a slow growth rate. Surgery is the treatment of choice, but the most frequent sites of origin (spine and skull base) make treatment of primary disease challenging. Local relapses affect more than 50% of cases, with a minority of patients being cured by further surgery. Furthermore, metastases occur in at least 20% of patients. For residual or recurrent disease, high-dose radiation therapy may be indicated. Radiation therapy is currently the preferred local treatment when surgery is problematic, exploiting most recent techniques, including proton beams and carbon ions. However, systemic therapy is needed in patients non-amenable to surgery and/or radiation therapy. We reviewed systemic treatments currently available, and targets possibly druggable in the future in this orphan disease.

AB - Chordoma is an exceedingly rare tumor, marked by a slow growth rate. Surgery is the treatment of choice, but the most frequent sites of origin (spine and skull base) make treatment of primary disease challenging. Local relapses affect more than 50% of cases, with a minority of patients being cured by further surgery. Furthermore, metastases occur in at least 20% of patients. For residual or recurrent disease, high-dose radiation therapy may be indicated. Radiation therapy is currently the preferred local treatment when surgery is problematic, exploiting most recent techniques, including proton beams and carbon ions. However, systemic therapy is needed in patients non-amenable to surgery and/or radiation therapy. We reviewed systemic treatments currently available, and targets possibly druggable in the future in this orphan disease.

KW - Bone sarcoma

KW - Chemotherapy

KW - Chordoma

KW - Sarcomas

KW - Systemic therapy options for unresectable and metastatic chordomas

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=80051664152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051664152&partnerID=8YFLogxK

U2 - 10.1007/s11912-011-0176-x

DO - 10.1007/s11912-011-0176-x

M3 - Article

C2 - 21584646

AN - SCOPUS:80051664152

VL - 13

SP - 323

EP - 330

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 4

ER -